Sartorius Stedim Biotech SA
PAR:DIM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
145.35
280
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DIM stock under the Base Case scenario is 159.09 EUR. Compared to the current market price of 175 EUR, Sartorius Stedim Biotech SA is Overvalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sartorius Stedim Biotech SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DIM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Sartorius Stedim Biotech SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and...
Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape.
As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.
Sartorius Stedim Biotech SA is a leading global supplier to the biopharmaceutical industry, primarily focusing on products and services that support the development and manufacturing processes of biopharmaceuticals. The company’s core business segments can be broadly categorized as follows:
-
Bioprocess Solutions:
- This segment offers a wide range of products and services for the entire bioprocessing workflow, including upstream and downstream processing. Key offerings include:
- Single-use bioreactors and bioprocess containers.
- Filtration and purification systems.
- Process analytics and monitoring tools.
- Automation solutions for process control and data integrity.
- This segment offers a wide range of products and services for the entire bioprocessing workflow, including upstream and downstream processing. Key offerings include:
-
Laboratory Products and Services:
- This segment includes analytical and laboratory equipment, consumables, and services tailored for research and quality control in the life sciences sector. Key products include:
- Laboratory balances, pipettes, and filtration devices.
- Cell culture media and reagents.
- Services such as calibration and maintenance of lab instrumentation.
- This segment includes analytical and laboratory equipment, consumables, and services tailored for research and quality control in the life sciences sector. Key products include:
-
Cell Culture Systems:
- Sartorius Stedim offers specific solutions designed for cell culture applications, vital for both research and production settings. This includes:
- Ready-to-use cell culture media and supplements.
- Bioreactors designed for optimal cell growth and productivity.
- Sartorius Stedim offers specific solutions designed for cell culture applications, vital for both research and production settings. This includes:
-
Services:
- Sartorius Stedim provides various service offerings, including consulting for process optimization, training seminars, and comprehensive maintenance services for their equipment and systems to ensure efficient operation in a high-stakes regulatory environment.
These core business segments allow Sartorius Stedim Biotech SA to serve a wide variety of customers in the biopharmaceutical market, aiding in the development and manufacture of biologics and vaccines, which have seen increasing demand due to advancements in medicine and biotechnology. The company's focus on innovation and high-quality products solidifies its position as a trusted partner in the life sciences industry.
Sartorius Stedim Biotech SA possesses several unique competitive advantages that distinguish it from its rivals in the biotechnology and biopharmaceutical sectors. Here are key areas where Sartorius Stedim Biotech excels:
-
Comprehensive Portfolio of Solutions: Sartorius offers a wide range of products and services that cover the entire biopharmaceutical value chain, including laboratory and production technologies. This holistic approach allows customers to streamline processes and reduce the complexity involved in drug development and production.
-
Strong Focus on Innovation: The company is heavily invested in research and development (R&D), continuously advancing its technologies and product offerings. This commitment to innovation enables Sartorius to stay ahead of market trends and regulatory changes, providing cutting-edge solutions to its customers.
-
Robust Global Presence: Sartorius has established a strong global footprint with manufacturing facilities, sales offices, and R&D centers across various continents. This global reach allows the company to better serve multinational clients and be responsive to regional market needs.
-
Strategic Partnerships and Collaborations: Sartorius has formed strategic alliances with key players in the biopharmaceutical industry. These collaborations enhance its technological capabilities and market position while facilitating access to new customer bases.
-
Customer-Centric Approach: Sartorius emphasizes building long-term relationships with its clients by providing tailored solutions and high-quality customer service. Their commitment to understanding specific customer needs helps in delivering customized services that enhance client satisfaction and loyalty.
-
Sustainability and Quality Commitment: Sartorius is committed to sustainable practices and high-quality standards. Its focus on quality management systems and regulatory compliance positions the company favorably in the eyes of clients who prioritize safety and efficacy in biopharmaceutical production.
-
Digitalization and Smart Manufacturing Initiatives: The company is at the forefront of digital transformation in the life sciences sector, incorporating smart manufacturing practices and intelligent systems into its products, which enhance efficiency and enable real-time monitoring of bioprocesses.
-
Expertise in Single-Use Technologies: Sartorius has a leading position in single-use technologies, which are increasingly preferred in biopharmaceutical manufacturing due to their flexibility, lower risk of cross-contamination, and cost-effectiveness. This expertise gives them an edge over competitors who may not have as advanced a product range in this area.
-
Strong Financial Performance: Sartorius has demonstrated consistent financial growth, which provides the resources for continuous investment in innovation, expansion, and enhancing its operational capabilities. A strong financial position also increases attractiveness to potential partners and customers.
By leveraging these competitive advantages, Sartorius Stedim Biotech positions itself as a leader in the biotech industry, ready to meet the evolving needs of its clients and the market.
Sartorius Stedim Biotech SA, like many companies in the biotech and pharmaceutical sectors, faces several risks and challenges that could impact its operations and growth in the near future. Here are some key factors to consider:
-
Regulatory Environment: The biotech industry is highly regulated. Changes in regulations, more stringent compliance requirements, or delays in approval processes for new products can impact Sartorius’s ability to bring products to market.
-
Market Competition: The bioprocessing and lab instrumentation markets are competitive, with both established players and new entrants. Sartorius must continuously innovate and improve its offerings to maintain its market position against peers.
-
Supply Chain Risks: Disruptions in the supply chain, whether due to geopolitical tensions, natural disasters, or pandemics, can affect production and lead to delays in meeting customer demand.
-
Technological Advancements: Rapid advancements in technology may render existing products or processes obsolete. Sartorius needs to invest in R&D to keep pace with innovation.
-
Customer Demand Fluctuation: Changes in customer demand, influenced by factors like shifts in healthcare policies, economic downturns, or changes in competitive landscapes, can impact Sartorius’s revenue.
-
Acquisitions and Integration Risks: Like many companies, Sartorius may pursue acquisitions to drive growth. However, integrating acquired companies and realizing synergies can be challenging and may not always yield the expected benefits.
-
Foreign Exchange Risk: As a global company, Sartorius is exposed to fluctuations in currency exchange rates, which can impact its financial performance.
-
Intellectual Property Challenges: Protecting intellectual property is crucial. Any infringement or challenges to Sartorius's patents could hinder its competitive edge.
-
Public Health Crises: While the pandemic has highlighted the importance of biotech, future health crises could disrupt operations, shift funding priorities, or change market dynamics unexpectedly.
-
Sustainability and Environmental Impact: Increasing scrutiny on corporate sustainability practices may require Sartorius to adapt its operations and product development strategies to meet environmental regulations and expectations.
Addressing these risks requires proactive strategic planning and effective risk management practices to ensure sustainable growth and profitability.
Revenue & Expenses Breakdown
Sartorius Stedim Biotech SA
Balance Sheet Decomposition
Sartorius Stedim Biotech SA
Current Assets | 1.7B |
Cash & Short-Term Investments | 475.3m |
Receivables | 363.3m |
Other Current Assets | 859m |
Non-Current Assets | 6.4B |
Long-Term Investments | 36.7m |
PP&E | 1.7B |
Intangibles | 4.6B |
Other Non-Current Assets | 61.4m |
Current Liabilities | 873.8m |
Accounts Payable | 203.2m |
Accrued Liabilities | 76.1m |
Other Current Liabilities | 594.5m |
Non-Current Liabilities | 3.3B |
Long-Term Debt | 2.8B |
Other Non-Current Liabilities | 540m |
Earnings Waterfall
Sartorius Stedim Biotech SA
Revenue
|
2.7B
EUR
|
Cost of Revenue
|
-1.6B
EUR
|
Gross Profit
|
1.1B
EUR
|
Operating Expenses
|
-752.4m
EUR
|
Operating Income
|
396.4m
EUR
|
Other Expenses
|
-227.2m
EUR
|
Net Income
|
169.2m
EUR
|
Free Cash Flow Analysis
Sartorius Stedim Biotech SA
EUR | |
Free Cash Flow | EUR |
In Q1 2024, the company displayed a mixed performance due to regional and segment variations. Order intake rose by around 10%, led by strong performances in the Americas, contrasting with weaker sales revenue, especially in China. Advanced Therapy Solutions showed promising growth, while equipment sales lagged. EBITDA margin stood robust at 28.6%, with continued efficiency improvements expected to sustain profitability. For the full year, they project mid- to high single-digit revenue growth and an EBITDA margin slightly above 30%, anticipating a stronger second half driven by consumables recovery and a rebound in equipment demand.
What is Earnings Call?
DIM Profitability Score
Profitability Due Diligence
Sartorius Stedim Biotech SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Sartorius Stedim Biotech SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
DIM Solvency Score
Solvency Due Diligence
Sartorius Stedim Biotech SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Sartorius Stedim Biotech SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DIM Price Targets Summary
Sartorius Stedim Biotech SA
According to Wall Street analysts, the average 1-year price target for DIM is 219.96 EUR with a low forecast of 135.34 EUR and a high forecast of 325.5 EUR.
Dividends
Current shareholder yield for DIM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DIM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one DIM stock under the Base Case scenario is 159.09 EUR.
Compared to the current market price of 175 EUR, Sartorius Stedim Biotech SA is Overvalued by 9%.